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Abstract 
A 68-year-old man with a clinical diagnosis of Alzheimer’s disease (AD) later developed 
amyotrophic lateral sclerosis (ALS), which was confirmed at autopsy at age 72 years. Because 
neuronal loss and AD-type pathologies (Braak stage II for neurofibrillary tangles) were scant, 
TDP-43-positive intracytoplasmic inclusions in hippocampal dentate granular cells and in 
neurons in the subiculum and amygdala, even though small in amount, may represent the 
earliest lesions of ALS-related dementia and could be the cause of dementia in this patient. 
Although the persistent elevation of creatine kinase from the onset could be a pointer to the 
presence of motor involvement, more accurate characterization of dementia, which may 
differentiate ALS-related dementia and AD, is necessary. 
 
Introduction 
The association of dementia with amyotrophic lateral sclerosis (ALS) is attracting 
increasing attention, especially after the identification of TDP-43 [1, 2], which may 
provide a molecular link between dementia and motor involvement. However, clinical 
features of dementia in ALS patients are too heterogeneous to be differentiated from 
other disorders accompanied with dementia. Some of these patients show memory 
impairments indistinguishable from AD-type dementia [3]. Ubiquitin/TDP-43-positive, 
tau-negative intraneuronal inclusions in the hippocampal dentate granular cells and  
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neurons of the transentorhinal cortex are candidates to explain memory impairments 
in ALS [3]. Here, we report an autopsy-confirmed ALS patient with an onset of memory 
impairments, diagnosed as AD-type dementia 3 years prior to the onset of ALS. Because 
AD-related lesions were scant, extramotor lesions, although limited to some TDP-43-
positive intraneuronal inclusions in the dentate gyrus, subiculum and amygdala, may 
be more plausible candidate lesions to explain the cognitive impairments in this ALS 
patient. 
Case Report 
A 68-year-old man was admitted to the endocrinology department of our hospital for the 
treatment of isolated ACTH deficiency. He had undergone coronary bypass graft for ischemic heart 
disease and pacemaker implantation because of recurrent attacks of syncope. He presented with 
severe delirium on the day of admission, which subsided after restoration of serum cortisone (1.11–
4.76 μg/dl; reference range 6.4–21) and sodium (118–130 mEq/l; reference range 138–146). Even 
after recovery from this episode of delirium, a neurologist and a psychiatrist found his memory 
impairment and apathy were persistent. The patient’s Hasegawa Dementia Scale score (revised 
Japanese version; HDS-R) [4] was 21/30 at the age of 68 years. Enlargement of inferior horns of 
lateral ventricles with medial temporal lobe atrophy shown on brain CT (fig. 1a) was compatible with 
the clinical diagnosis of possible AD (NINCDS-ADRDA criteria) [5]. Brain SPECT showed 
hypoperfusion of the bilateral parietal lobe, but in the frontal, temporal, and posterior cingulate 
lesions, AD-characteristic changes were not evident (fig. 1b). 
Three years later, at the age of 72 years, the patient complained of muscle weakness and 
dysphagia, even though ACTH deficiency was stable and well controlled. On admission to our 
neurology department, upper and lower motor neuron involvement in the cranial region and all limbs 
was noted. Needle electromyography demonstrated spontaneous activities and a poor interference 
pattern with long-duration, high-amplitude potentials in the muscles examined. The clinical diagnosis 
of definite ALS was made. In addition to memory disturbance (HDS-R 20/30), delayed recall and 
category fluency were impaired. Moreover, indifference and apathy became more evident. Although 
abnormal behaviors were not apparent, he refused taking liquid food and tracheal suction, in spite of 
severe dysphagia. On brain CT repeated at the age of 72 years (fig. 1c), ischemic changes were not 
evident, and progression of atrophy was not remarkable in comparison to the brain CT performed at 
the age of 68 years. Serum creatine kinase was persistently elevated up to 575 IU/l (200–330; 
reference range 35–175) during the entire clinical course of 4 years. 
The patient suffered from acute respiratory failure and died of pneumonia at the age of 72 years. 
His clinical course of dementia lasted 4 years, with additional motor symptoms during the last year. A 
general autopsy disclosed generalized atrophy of muscles, including respiratory muscles and 
bronchopneumonia, as an immediate cause of death. 
The brain weighed 1,270 g after fixation. Macroscopically, thin diaphragms and anterior spinal 
roots were noted. Transverse section of the cervical cord stained with the Klüver-Barrera method 
disclosed mild degeneration of bilateral pyramidal tracts (fig. 1d). Microscopic findings included mild 
spongiosis in layer II of the precentral cortex and fallout of motor neurons in the anterior horn and 
cranial nuclei. Bunina bodies, skein-like inclusions positive for ubiquitin and cytoplasmic inclusions 
positive for phosphorylated TDP-43 were also found in these lower motor nuclei (fig. 1e–h). In 
contrast with these definite pathological changes of ALS, neurofibrillary tangle (NFT) stage according 
to Braak was II and Aβ-positive deposits were rare, the quantity hardly explaining the clinically overt 
dementia. α-Synuclein deposits and argyrophilic grains were absent throughout the brain. Neuronal 
loss was restricted to the precentral cortex, where no NFTs were found. Although the nucleus basalis 
of Meynert, basal ganglia, thalamus, substantia nigra, white matter and cortices in the frontal, 
temporal and parietal lobes and amygdala were well preserved, hippocampal dentate granular cells 
contained a few neuronal cytoplasmic inclusions positive for phosphorylated TDP-43 but negative for 
ubiquitin (fig. 1i). Similar inclusions were found in the subiculum and amygdala.   
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Discussion 
This patient had a 3-year clinical history of AD-type dementia before being 
diagnosed as having ALS, which was ultimately confirmed at autopsy based on 
cytopathological changes characteristic of ALS, such as Bunina bodies, TDP-43-positive 
inclusions and skein-like inclusions. Initial memory impairment with bilateral 
hippocampal atrophy naturally led to the clinical diagnosis of AD [5], as interpreted by 
two independent specialists (neurologist and psychiatrist) at a university hospital. 
Neuropathological examination, however, did not support this diagnosis because NFTs 
were scant (Braak stage II) and Aβ-positive deposits were rare. Lewy bodies, 
argyrophilic grains and Pick bodies were absent. Although these age-related, 
quantitative changes were not abundant enough to explain overt clinical dementia, 
extramotor lesions possibly linked to cognitive impairment in ALS were found in form 
of TDP-43-positive intracytoplasmic inclusions in the hippocampal dentate granular 
cells and neurons in the subiculum and amygdala; in contrast, the neuritic profile was 
scant, compatible with type 2 according to the Sampathu-Neumann classification [2]. In 
addition to these qualitative cellular markers for ALS and ALS-related dementia, 
restricted spongiosis was found in the premotor cortex, where NFTs and Aβ deposits 
were absent, again suggestive of ALS. 
Cognitive deficits associated with ALS can be highly variable [6], and clinical 
differentiation from other causes of dementia is quite a challenge. Although it is 
generally considered as frontotemporal dementia of non-AD type [7], more specific 
clinical clues have been proposed [8] but have not always been found to be useful to 
characterize ALS-related dementia. Moreover, memory impairment as an initial 
manifestation of dementia in ALS patients has been reported [9], and the possible 
association of AD pathology with ALS may further complicate the interpretation [10]. 
Since the involvement of the so-called hippocampal perforant pathway in ALS could be 
severe enough to cause memory impairments in some ALS patients even in the absence 
of AD pathology [3], memory impairment as an initial manifestation of dementia does 
not necessarily favor the diagnosis of AD as in our patient. 
In retrospect, cognitive impairment of this patient, initially compatible with AD, has 
evolved over the next 3 years, and he showed indifference and apathy even when his 
HDS-R score still remained 20. Although this progressive course suggests some 
degenerative process, it is surprising that AD lesions were scant and ALS-related 
pathology in relevant areas was minimal. Currently, diagnostic criteria for ALS-related 
dementia are not yet available, probably because of the heterogeneity in this disease’s 
clinical manifestations and the diversity of its pathological features [11]. However, the 
presence of TDP-43-positive intracytoplasmic inclusions in the dentate gyrus indicates 
extramotor extension of ALS-related lesions. Because similar inclusions could be 
present even in ALS patient without overt dementia [12], it is not yet possible to decide 
whether the ALS-related inclusions in this patient may explain his cognitive deficits. 
Considering the absence of other specific cytopathologies, however, we are left with the 
possibility that the extramotor pathology of this patient represents the earliest lesions 
of dementia related to ALS. This interpretation paves the way for early therapeutic 
intervention in ALS-related dementia before neuronal depletion and specific 
cytopathologies are florid. It is of note that creatine kinase was elevated throughout the 
disease course, which may alert the presence of ALS but usually is not seen in AD  
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patients. Indeed, a patient with non-AD-type dementia with elevated creatine kinase 
was found to have ALS-related dementia, even though motor deficits were clinically 
absent throughout the course [13]. This awareness might have prompted examination 
with needle electromyography at an earlier stage even before motor deficits were 
manifesting. 
In summary, we report an autopsy-confirmed ALS patient. Because AD pathology 
was too scant to explain his initial amnesia masquerading AD, extramotor lesions of 
ALS, although limited, may represent the earliest stage of dementia related to ALS, 
which may allow early therapeutic intervention hopefully available in the near future. 
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Fig. 1. a Brain CT at age 68. Enlargement of bilateral inferior horns of lateral ventricles with mild 
medial temporal lobe atrophy. b Brain SPECT at age 68. Hypoperfusion of the bilateral parietal lobe. 
c Brain CT at age 72. Progression of atrophy was not remarkable in comparison to a. d Cervical spine. 
Bilateral mild pyramidal tracts degeneration. The arrows and arrowheads point to the anterior and 
posterior roots, respectively. e–h ALS-specific cytoplasmic inclusions in lower motor neurons. Bar: 50 
μm. e, f Bunina bodies in a hypoglossal nucleus (e) and lumbar spinal motor neuron immunopositive 
for cystatin C (f). g Skein-like inclusion in a hypoglossal nucleus immunopositive for ubiquitin. 
h Cytoplasmic inclusion in a lumbar spinal motor neuron immunopositive for phosphorylated  
TDP-43. i, j Cytoplasmic inclusions immunopositive for TDP-43 in the hippocampal dentate gyrus (i) 
and amygdala (j). Bar: 50 μm. d Klüver-Barrera stain. e Hematoxylin and eosin stain. f Immunostain 
with anti-cystatin C. g Immunostain with anti-ubiquitin. h–j Immunostain with anti-phosphorylated 
TDP-43. 
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